NOV 06, 2023 – Originally published Armageddon Prose: COVID Shots Cause Strokes, The Science™ Concedes “Older adults who received last year’s COVID booster and a high-dose version of the flu vaccine in a recent study may have a potential increased risk of stroke, according to a new FDA-funded research project. Experts urged that the results […]
Laura J. Rasmussen-Torvik, Published, 2023 – More infoView PDF Journal of Clinical Investigation, Guy Hazan, … , David Greenberg, Jeffrey A. Haspel, Clinical Medicine COVID-19 Vaccines In this issue of the JCI, Hazan et al. (1) report on whether time of day of COVID vaccination associates with subsequent breakthrough COVID-19 infection in 1,515,754 patients, using data from a large […]
According to InsuranceNewsNet, insurers are especially concerned by data from the Centers for Disease Control and Prevention that show “mortality rates alarmingly rising for different categories,” including younger adult mortality rates that are up more than 20% above historic norms in 2023. By Mike Capuzzo, The Defender’s Top News of the Day. Executives at the largest […]
Theo Sanderson, Ryan Hisner, I’ah Donovan-Banfield, Hassan Hartman, Alessandra Løchen, Thomas P. Peacock & Christopher Ruis Nature (2023) Cite this article Abstract Molnupiravir, an antiviral medication widely used against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), acts by inducing mutations in the virus genome during replication. Most random mutations are likely to be deleterious to the virus and many will be lethal; thus, molnupiravir-induced […]
Susanna Naggie, MD, MHS1,2; David R. Boulware, MD, MPH3; Christopher J. Lindsell, PhD4; et alThomas G. Stewart, PhD5; Alex J. Slandzicki, MD6; Stephen, C. Lim, MD Jonathan Cohen, MD8; David Kavtaradze, MD9, Arch Amon, MD10, et. al for the Accelerating Covid-19 Therapeutic Interventions and Vaccines (ACTIV)-6 Study Group and Investigators. JAMA. 2023;329(11):888-897. doi:10.1001/jama.2023.1650 Question Does ivermectin, with a maximum targeted dose of 600 μg/kg daily for 6 days, compared with placebo, shorten symptom duration among adult (≥30 years) outpatients with symptomatic […]
Maxime Taquet, Zuzanna Skorniewska, Adam Hampshire, James D. Chalmers, Ling-Pei Ho, Alex Horsley, Michael Marks, Krisnah Poinasamy, Betty Raman, Olivia C. Leavy, Matthew Richardson, Omer Elneima, Hamish J. C. McAuley, Aarti Shikotra, Amisha Singapuri, Marco Sereno, Ruth M. Saunders, Victoria C. Harris, Linzy Houchen-Wolloff, Neil J. Greening, Parisa Mansoori, Ewen M. Harrison, Annemarie B. Docherty, Nazir I. Lone, PHOSP-COVID Study Collaborative Group, Nature Medicine (August 2023) Abstract Post-COVID cognitive deficits, including ‘brain fog’, are clinically complex, with both objective and […]
Janessa Y.J. Tan,1 Danielle E. Anderson,2,3 Abhay P.S. Rathore,4 Aled O’Neill,1 Chinmay Kumar Mantri,1 Wilfried A.A. Saron,1 Cheryl Q.E. Lee,5 Chu Wern Cui,5 Adrian E.Z. Kang,1 Randy Foo,1 Shirin Kalimuddin,1,6 Jenny G. Low,1,6 Lena Ho,5 Paul Tambyah,7,8 Thomas W. Burke,9 Christopher W. Woods,9,10 Kuan Rong Chan,1 Jörn Karhausen,4,11 and Ashley L. St. John1,4,12,13 Published August 10, 2023 – 10.1172/JCI149834 Journal of Clinical Investigation Lung inflammation is a hallmark of Coronavirus disease 2019 (COVID-19) in patients […]
November 2, 2023, NEJM Abstract BACKGROUND The efficacy of simvastatin in critically ill patients with coronavirus disease 2019 (Covid-19) is unclear. METHODS In an ongoing international, multifactorial, adaptive platform, randomized, controlled trial, we evaluated simvastatin (80 mg daily) as compared with no statin (control) in critically ill patients with Covid-19 who were not receiving statins […]
Siriruk Changrob,1 Peter J. Halfmann,2 Hejun Liu,3 Jonathan L. Torres,3 Joshua J.C. McGrath,1 Gabriel Ozorowski,3 Lei Li,1 G. Dewey Wilbanks,1 Makoto Kuroda,2 Tadashi Maemura,2 Min Huang,1 Nai-Ying Zheng,1 Hannah L. Turner,3 Steven A. Erickson,4 Yanbin Fu,1 Atsuhiro Yasuhara,1 Gagandeep Singh,5,6 Brian Monahan,6,7 Jacob Mauldin,6,7 Komal Srivastava,6,7 Viviana Simon,5,6,7,8,9 Florian Krammer,5,6,7 D. Noah Sather,10,11,12 Andrew B. Ward,3 Ian A. Wilson,3,13 Yoshihiro Kawaoka,2,14,15,16 and Patrick C. Wilson1,Published 2023 – 10.1172/JCI166844 Abstract The rapid evolution of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variants […]
James May, Jane A. Mitchell, and R. Gisli Jenkins, Published September 15, 2023 – 10.1172/JCI172058 Idiopathic pulmonary fibrosis (IPF) is a progressive scarring disease of the lung with poor survival. The incidence and mortality of IPF are rising, but treatment remains limited. Currently, two drugs can slow the scarring process but often at the expense of intolerable side […]